Stay updated on Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now presents the ClinicalTrials.gov record for a nivolumab, radiation therapy, and bevacizumab study for recurrent glioblastoma, with details about participation, treatment, outcomes, and locations.
    Difference
    58%
    Check dated 2026-11-11T00:37:11.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-03T23:15:13.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A notice about NIH website terminology appears above the 403 error page. The site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:41:07.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision indicator changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T22:45:39.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a Home link. This replaces the study record content and removes the detailed trial sections such as eligibility criteria and listed locations.
    Difference
    19%
    Check dated 2026-09-23T00:42:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page's revision metadata was updated from v3.6.6 to v3.7.0, indicating a newer version of the study entry. This update appears to be a backend or documentation change rather than a modification to the study details, eligibility criteria, or results.
    Difference
    0.1%
    Check dated 2026-09-15T23:47:41.000Z thumbnail image

Stay in the know with updates to Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+RT+Bevacizumab in Recurrent Methylated Glioblastoma Clinical Trial page.